Histologic conversion in the non-Hodgkin's lymphomas

B. Acker, R. T. Hoppe, T. V. Colby, R. S. Cox, H. S. Kaplan, S. A. Rosenberg

Research output: Contribution to journalArticle

169 Citations (Scopus)

Abstract

Between July 1, 1971 and December 31, 1978, 150 patients with favorable subtypes of non-Hodgkin's lymphoma [nodular poorly differentiated lymphocytic (NLPD), nodular mixed, or diffuse well differentiated lymphocytic] were entered into prospective randomized clinical trials at Stanford University. Treatments included involved field, total lymphoid, or whole body irradiation, single alkylating agent chemotherapy, combination chemotherapy with cyclophosphamide, vincristine and prednisone (CVP) or with cyclophosphamide, vincristine, procarbazine, and prednisone (C-MOPP), or various combinations of chemotherapy and irradiation. The initial complete response rate (CR) was 79%. Among patients who achieved a CR, 31% later relapsed. There were 78 patients who either failed to achieve a CR or achieved a CR and later relapsed. Histologic conversion (change from initially favorable to an unfavorable subtype of non-Hodgkin's lymphoma) was documented in 22/78 patients (28%). However, the actuarial risk for conversion was actually much greater (60% at 8 yr). The median time to documentation of conversion was 51 mo. The most common type of histologic conversion was from NLPD to diffuse histiocytic lymphoma. Documented histologic conversion was often associated with a more aggressive clinical behavior of the lymphoma, and the median survival after conversion was less than 1 yr. However, those patients who achieved a CR after conversion had a more favorable outcome (actuarial survival 75% at 5 yr). No specific risk factors predictive of histologic conversion could be identified.

Original languageEnglish (US)
Pages (from-to)11-16
Number of pages6
JournalJournal of Clinical Oncology
Volume1
Issue number1
StatePublished - 1983
Externally publishedYes

Fingerprint

Non-Hodgkin's Lymphoma
Whole-Body Irradiation
Vincristine
Prednisone
Combination Drug Therapy
Cyclophosphamide
Procarbazine
Survival
Lymphoma, Large B-Cell, Diffuse
Alkylating Agents
Documentation
Lymphoma
Randomized Controlled Trials
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Acker, B., Hoppe, R. T., Colby, T. V., Cox, R. S., Kaplan, H. S., & Rosenberg, S. A. (1983). Histologic conversion in the non-Hodgkin's lymphomas. Journal of Clinical Oncology, 1(1), 11-16.

Histologic conversion in the non-Hodgkin's lymphomas. / Acker, B.; Hoppe, R. T.; Colby, T. V.; Cox, R. S.; Kaplan, H. S.; Rosenberg, S. A.

In: Journal of Clinical Oncology, Vol. 1, No. 1, 1983, p. 11-16.

Research output: Contribution to journalArticle

Acker, B, Hoppe, RT, Colby, TV, Cox, RS, Kaplan, HS & Rosenberg, SA 1983, 'Histologic conversion in the non-Hodgkin's lymphomas', Journal of Clinical Oncology, vol. 1, no. 1, pp. 11-16.
Acker B, Hoppe RT, Colby TV, Cox RS, Kaplan HS, Rosenberg SA. Histologic conversion in the non-Hodgkin's lymphomas. Journal of Clinical Oncology. 1983;1(1):11-16.
Acker, B. ; Hoppe, R. T. ; Colby, T. V. ; Cox, R. S. ; Kaplan, H. S. ; Rosenberg, S. A. / Histologic conversion in the non-Hodgkin's lymphomas. In: Journal of Clinical Oncology. 1983 ; Vol. 1, No. 1. pp. 11-16.
@article{fde07ae94da34f3992069d0d53342a24,
title = "Histologic conversion in the non-Hodgkin's lymphomas",
abstract = "Between July 1, 1971 and December 31, 1978, 150 patients with favorable subtypes of non-Hodgkin's lymphoma [nodular poorly differentiated lymphocytic (NLPD), nodular mixed, or diffuse well differentiated lymphocytic] were entered into prospective randomized clinical trials at Stanford University. Treatments included involved field, total lymphoid, or whole body irradiation, single alkylating agent chemotherapy, combination chemotherapy with cyclophosphamide, vincristine and prednisone (CVP) or with cyclophosphamide, vincristine, procarbazine, and prednisone (C-MOPP), or various combinations of chemotherapy and irradiation. The initial complete response rate (CR) was 79{\%}. Among patients who achieved a CR, 31{\%} later relapsed. There were 78 patients who either failed to achieve a CR or achieved a CR and later relapsed. Histologic conversion (change from initially favorable to an unfavorable subtype of non-Hodgkin's lymphoma) was documented in 22/78 patients (28{\%}). However, the actuarial risk for conversion was actually much greater (60{\%} at 8 yr). The median time to documentation of conversion was 51 mo. The most common type of histologic conversion was from NLPD to diffuse histiocytic lymphoma. Documented histologic conversion was often associated with a more aggressive clinical behavior of the lymphoma, and the median survival after conversion was less than 1 yr. However, those patients who achieved a CR after conversion had a more favorable outcome (actuarial survival 75{\%} at 5 yr). No specific risk factors predictive of histologic conversion could be identified.",
author = "B. Acker and Hoppe, {R. T.} and Colby, {T. V.} and Cox, {R. S.} and Kaplan, {H. S.} and Rosenberg, {S. A.}",
year = "1983",
language = "English (US)",
volume = "1",
pages = "11--16",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Histologic conversion in the non-Hodgkin's lymphomas

AU - Acker, B.

AU - Hoppe, R. T.

AU - Colby, T. V.

AU - Cox, R. S.

AU - Kaplan, H. S.

AU - Rosenberg, S. A.

PY - 1983

Y1 - 1983

N2 - Between July 1, 1971 and December 31, 1978, 150 patients with favorable subtypes of non-Hodgkin's lymphoma [nodular poorly differentiated lymphocytic (NLPD), nodular mixed, or diffuse well differentiated lymphocytic] were entered into prospective randomized clinical trials at Stanford University. Treatments included involved field, total lymphoid, or whole body irradiation, single alkylating agent chemotherapy, combination chemotherapy with cyclophosphamide, vincristine and prednisone (CVP) or with cyclophosphamide, vincristine, procarbazine, and prednisone (C-MOPP), or various combinations of chemotherapy and irradiation. The initial complete response rate (CR) was 79%. Among patients who achieved a CR, 31% later relapsed. There were 78 patients who either failed to achieve a CR or achieved a CR and later relapsed. Histologic conversion (change from initially favorable to an unfavorable subtype of non-Hodgkin's lymphoma) was documented in 22/78 patients (28%). However, the actuarial risk for conversion was actually much greater (60% at 8 yr). The median time to documentation of conversion was 51 mo. The most common type of histologic conversion was from NLPD to diffuse histiocytic lymphoma. Documented histologic conversion was often associated with a more aggressive clinical behavior of the lymphoma, and the median survival after conversion was less than 1 yr. However, those patients who achieved a CR after conversion had a more favorable outcome (actuarial survival 75% at 5 yr). No specific risk factors predictive of histologic conversion could be identified.

AB - Between July 1, 1971 and December 31, 1978, 150 patients with favorable subtypes of non-Hodgkin's lymphoma [nodular poorly differentiated lymphocytic (NLPD), nodular mixed, or diffuse well differentiated lymphocytic] were entered into prospective randomized clinical trials at Stanford University. Treatments included involved field, total lymphoid, or whole body irradiation, single alkylating agent chemotherapy, combination chemotherapy with cyclophosphamide, vincristine and prednisone (CVP) or with cyclophosphamide, vincristine, procarbazine, and prednisone (C-MOPP), or various combinations of chemotherapy and irradiation. The initial complete response rate (CR) was 79%. Among patients who achieved a CR, 31% later relapsed. There were 78 patients who either failed to achieve a CR or achieved a CR and later relapsed. Histologic conversion (change from initially favorable to an unfavorable subtype of non-Hodgkin's lymphoma) was documented in 22/78 patients (28%). However, the actuarial risk for conversion was actually much greater (60% at 8 yr). The median time to documentation of conversion was 51 mo. The most common type of histologic conversion was from NLPD to diffuse histiocytic lymphoma. Documented histologic conversion was often associated with a more aggressive clinical behavior of the lymphoma, and the median survival after conversion was less than 1 yr. However, those patients who achieved a CR after conversion had a more favorable outcome (actuarial survival 75% at 5 yr). No specific risk factors predictive of histologic conversion could be identified.

UR - http://www.scopus.com/inward/record.url?scp=0020962350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020962350&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 11

EP - 16

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -